Wyeth extends TNF accord with Ablynx for one more year
Belgian drugmaker Ablynx says that its tumor necrosis factor-alpha partnership with US drug major Wyeth has been extended for another year. The two firms are collaborating to discover and develop novel therapeutics against TNF-alpha.
As part of the collaboration, Ablynx receives research funding and will be entitled to future milestone payments and royalties upon commercialization. Further financial details were not disclosed.
Frank Walsh, executive vice president, head of discovery research of Wyeth said: "we continue to be excited about the potential of Ablynx's Nanobody technology as a platform for next-generation therapeutics targeted to TNF-alpha. We look forward to our ongoing collaboration with Ablynx with the goal of bringing new therapies to patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze